Analyst estimates up to $1.2 billion in annual Lilly sales from Medicare GLP-1 Bridge

The Medicare GLP-1 Bridge, an 18-month demonstration that pays for GLP-1 medicines used for weight loss, signed up more than 500,000 beneficiaries in its first two months, the White House said on Aug. 31 ^[1][2]. The White House also said those patients saved $216 million on the drugs ^[1][2]. In a separate White House press conference, CMS Administrator Mehmet Oz said "600,000 seniors already, just in two months, have signed up to get these medications" ^[1]. The two figures have not been reconciled publicly.

Jefferies analyst Akash Tewari annualized the two-month numbers to $1.5 billion to $1.8 billion in revenue across the program at the $245 monthly net price manufacturers charge CMS ^[1][2]. Applying Lilly's roughly 60% share of U.S. obesity volume, he estimated $900 million to $1.2 billion of that would go to Lilly ^[1]. The White House has not broken down the program's split between Lilly and Novo Nordisk ^[1].

How the program works

The Bridge opened July 1, 2026, and runs through Dec. 31, 2027 ^[2]. CMS pays manufacturers $245 per monthly supply while beneficiaries pay a flat $50 copay ^[1][2]. The demonstration sits outside Part D, so plan sponsors carry no risk; Humana is the single national processor for prior authorization, claims and pharmacy payment ^[2].

Covered products are Lilly's Foundayo (orforglipron) tablets, Novo Nordisk's Wegovy injection and tablets, and Lilly's Zepbound KwikPen only ^[2]. Ozempic, Mounjaro and Rybelsus remain in Part D for their other labeled uses ^[2]. To qualify, a beneficiary must be 18 or older, enrolled in an eligible Part D plan, and prescribed a covered product solely to reduce or maintain body weight, with a BMI of 35 or higher; or a BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse chronic kidney disease; or a BMI of 27 or higher plus prediabetes, a prior heart attack, a prior stroke or symptomatic peripheral artery disease ^[2]. People with type 2 diabetes, moderate to severe obstructive sleep apnea or noncirrhotic MASH with fibrosis are steered back to Part D, as is anyone already filling a GLP-1 under Part D in 2026 ^[2].

Tewari calculated about 1.85 fills per enrollee over two months, which he read as strong early adherence and conversion ^[1][2]. He said the run rate implies roughly 25% penetration of the eligible pool within another month or two, with growth likely slowing after that ^[1]. Using the White House savings figure and Oz's 600,000 sign-ups, he said the implied fill count would drop meaningfully if the benchmark price were $350 a month, the price offered on the federal TrumpRx platform, rather than $245 ^[1]. The $245 price is paid to the government, not by patients ^[1].

Estimates of who is eligible differ widely. KFF put the residual Bridge-eligible group at 3.8 million Part D enrollees, or about 8% of enrollment ^[1][2]. Lilly has cited roughly 20 million, a figure the Syenza report describes as the broader clinical obesity burden in Medicare rather than the Bridge-only group ^[2]. Tewari said the real potential likely lies "somewhere in between" ^[1]. CVS and Walgreens each reported about 100,000 Bridge fills in late August ^[2].

Why it matters for patients

The $50 copay does not fall under Extra Help, does not count toward the Part D deductible or the $2,100 out-of-pocket cap, and does not appear on the Part D explanation of benefits ^[2]. The Medicare Prescription Payment Plan cannot spread it across the year, coupons and discount cards cannot be stacked, and the program does not coordinate with other insurance ^[2]. Prior authorization requires a prescriber to attest the drug is for weight reduction plus structured nutrition and activity; CMS says most early requests cleared in under 12 hours, with decisions mailed within 72 hours of a complete submission ^[2]. Approval runs through Dec. 31, 2027, including refills and dose changes, unless the patient switches GLP-1 products; there is no appeals process, though a prescriber can resubmit if the facts were wrong ^[2].

Because the program excludes people with diabetes, sleep apnea or MASH, a patient with obesity plus diabetes can face a higher Part D copay than a neighbor who qualifies for the Bridge at $50 ^[2].

What happens next

KFF sketched federal costs at $195 net per fill, about $1.3 billion over 18 months if 10% of the eligible pool participates and fills every month, rising to $3.3 billion at 25%, $6.7 billion at 50% and $10 billion at 75%; those are mechanical scenarios, not budget scores ^[2]. The open questions through 2027 are whether the early sign-ups were a one-time surge or a run rate, how the Lilly versus Novo mix splits, and what adherence looks like at six and twelve months ^[2]. Tewari said he expects growth might slow later ^[1]. The sunset in December 2027 is the next fixed date, and the question of whether CMS tries again to fold obesity GLP-1s into Part D bidding for 2028 has not been decided ^[2].